Research Topics

Alexandre Vallée



  1. Vallée A, Vallée J. Warburg effect hypothesis in autism Spectrum disorders. Mol Brain. 2018;11:1 pubmed publisher
    ..Dysregulation of energetic metabolism might promote cell deregulation and progression of ASD. Warburg effect regulation could be an attractive target for developing therapeutic interventions in ASD. ..
  2. Vallée A, Lecarpentier Y, Guillevin R, Vallée J. Thermodynamics in Neurodegenerative Diseases: Interplay Between Canonical WNT/Beta-Catenin Pathway-PPAR Gamma, Energy Metabolism and Circadian Rhythms. Neuromolecular Med. 2018;: pubmed publisher
    ..Thermodynamics rhythms operate far-from-equilibrium and partly regulate interactions between WNT/beta-catenin pathway and PPAR gamma. In NDs, metabolism, thermodynamics and circadian rhythms are tightly interrelated. ..
  3. Vallée A, Lecarpentier Y, Vallee J. Thermodynamic Aspects and Reprogramming Cellular Energy Metabolism during the Fibrosis Process. Int J Mol Sci. 2017;18: pubmed publisher
  4. Vallée A, Lecarpentier Y, Guillevin R, Vallée J. Aerobic Glycolysis Hypothesis Through WNT/Beta-Catenin Pathway in Exudative Age-Related Macular Degeneration. J Mol Neurosci. 2017;62:368-379 pubmed publisher
    ..Photoreceptors in retina cells can metabolize glucose through aerobic glycolysis to protect them against oxidative damage, as cancer cells do. ..
  5. Vallée A, Lecarpentier Y, Guillevin R, Vallee J. PPAR? agonists: Potential treatments for exudative age-related macular degeneration. Life Sci. 2017;188:123-130 pubmed publisher
    ..In exudative AMD, PPAR? agonists downregulate inflammation and the WNT/?-catenin pathway. PPAR? agonists can appear as promising treatment against the initiation and the progression of CNV in exudative AMD. ..
  6. Vallée A, Vallée J, Guillevin R, Lecarpentier Y. Interactions Between the Canonical WNT/Beta-Catenin Pathway and PPAR Gamma on Neuroinflammation, Demyelination, and Remyelination in Multiple Sclerosis. Cell Mol Neurobiol. 2018;38:783-795 pubmed publisher
    ..PPAR gamma agonists appear as a promising treatment for the inhibition of demyelination and the promotion of proper remyelination through the control of both NF-kappaB activity and canonical WNT/beta-catenin pathway. ..

Detail Information